Halil GenÇ

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2504353/publications.pdf

Version: 2024-02-01

20	075	567281	552781
30	875	15	26
papers	citations	h-index	g-index
30	30	30	1626
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The relationship between blood urea nitrogen levels and metabolic, biochemical, and histopathologic findings of nondiabetic, nonhypertensive patients with nonalcoholic fatty liver disease. Turkish Journal of Medical Sciences, 2016, 46, 985-991.	0.9	5
2	Choroidal Thickness Changes in the Acute Attack Period in Patients with Familial Mediterranean Fever. Ophthalmologica, 2016, 235, 72-77.	1.9	28
3	Neutrophil-to-lymphocyte ratio is not a predictor of liver histology in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1144-1148.	1.6	23
4	Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 2015, 13, 319-325.	1.3	31
5	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. Journal of Clinical Lipidology, 2015, 9, 576-582.	1.5	56
6	The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi Journal of Gastroenterology, 2015, 21, 139.	1.1	21
7	The relationship of serum uric acid with non-alcoholic fatty liver disease. Clinical Biochemistry, 2014, 47, 383-388.	1.9	62
8	Carotid atherosclerosis or nonalcoholic fatty liver disease: Which comes first?. Atherosclerosis, 2013, 231, 187-188.	0.8	3
9	Plasma fetuinâ€∢scp>A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clinical Endocrinology, 2013, 78, 712-717.	2.4	73
10	Non-alcoholic fatty liver disease per se is not associated with carotid atherosclerosis. Gulhane Medical Journal, 2013, 55, 84.	0.2	6
11	Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Annals of Hepatology, 2013, 12, 380-387.	1.5	83
12	The presence of <i>MEFV </i> gene mutations in patients with primary osteoarthritis who require surgery. Korean Journal of Internal Medicine, 2013, 28, 594.	1.7	4
13	Efficacy of a Modified Sequential Therapy Including Bismuth Subcitrate as Firstâ€Line Therapy to Eradicate <i> <scp>H</scp>elicobacter pylori</i> in a Turkish Population. Helicobacter, 2012, 17, 486-490.	3.5	9
14	Soluble CD40 ligand, soluble P-selectin and von Willebrand factor levels in subjects with prediabetes: The impact of metabolic syndrome. Clinical Biochemistry, 2012, 45, 92-95.	1.9	13
15	C reactive protein levels in non-alcoholic fatty liver disease. Journal of Hepatology, 2012, 56, 507-508.	3.7	3
16	Elevated asymmetric dimethylarginine in plasma: An early marker for endothelial dysfunction in non-alcoholic fatty liver disease?. Diabetes Research and Clinical Practice, 2012, 96, 47-52.	2.8	39
17	Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scandinavian Journal of Gastroenterology, 2011, 46, 1355-1361.	1.5	16
18	Non-invasive prediction of fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2011, 55, 498-499.	3.7	0

#	Article	IF	CITATIONS
19	Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. Endocrine, 2010, 37, 455-459.	2.3	30
20	Microalbuminuria and nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2010, 59, e5.	3.4	0
21	Plasma Apelin and ADMA Levels in Patients with Essential Hypertension. Clinical and Experimental Hypertension, 2010, 32, 179-183.	1.3	82
22	Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease. Upsala Journal of Medical Sciences, 2010, 115, 253-259.	0.9	46
23	Circulating levels of interleukin-18 in patients with non-alcoholic fatty liver disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 399-403.	1.2	11
24	Comment and reply on: Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2010, 45, 1000-1002.	1.5	3
25	Transforming growth factor \hat{l}^2 (TGF- \hat{l}^2) levels in otherwise healthy subjects with impaired glucose tolerance. Endokrynologia Polska, 2010, 61, 691-4.	1.0	O
26	LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis, 2009, 204, 222-228.	0.8	45
27	Platelet Aggregation is not Enhanced in Patients with Prediabetes. Upsala Journal of Medical Sciences, 2007, 112, 338-346.	0.9	2
28	Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Research and Clinical Practice, 2007, 76, 24-29.	2.8	178
29	Soluble CD40 Ligand Levels in Otherwise Healthy Subjects With Impaired Fasting Glucose. Mediators of Inflammation, 2006, 2006, 1-5.	3.0	3

30 İNFLAMATUAR BAÄžIRSAK HASTALIKLARININ KOROİDAL VE MAKULAR KALINLIK ÜZERİNE ETKİSİ. Sþleyman Demirel Üniversitesi Tıp Fakþltesi Dergisi, 0, , .